Here's one that's interesting:
OC49. Cognitive decline, hippocampal atrophy and amyloid accumulation in preclinical and prodromal AD : Clinical trial implications
Paul Maruff, PhD 1,2,6, Yen Ying Lim2, Robert H. Pietrzak3, David Ames4, 6 Kathryn A. Ellis4, 6, Colin L. Masters2,4,6, Christopher C. Rowe5, 6, Victor L. Villemagne5, 6.
(1) CogState Ltd (2) The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia. (3) Yale University Medical School, (4) The University of Melbourne (5) Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia (6) For the AIBL Research Group
OK, everyone keeps saying "off-label" use for AD. Who's going to pay out pf pocket the 5-10K per MONTH PBT2 out of thier own pocket. Off label won't be covered by insurance and the orphan designation means the price will be VERY HIGH. There won't be much off label use I would say..
What he's saying it Tanzi knew before the Imagine results that PBT2 did well in his matrix. My problem is the Imagine results were not good. So what does that say about how well the matrix will relate to real in-patient testing?
They just sold 3 million shares for 6.83 to lincoln as part of the prior financing deal. Price of the shares obviously set for the close of the day before results announced so they get a good price.
I like the ending paragraph:
“Our goal was to prevent further progression of the disease, not reverse it and see visual improvement,” says Lanza. “But seeing the improvement in vision was frosting on the cake.”
Article is gone but should be coming soon in the Lancet.
Vision Archives - Today's Practitioner
22 hours ago - ... distance activities, and peripheral vision.By Stephen D Schwartz, Robert Lanza et al, published in The Lancet, Oct. 2014. Continue Reading.
How will it bolster accelerated approval? I haven't heard anything about the FDA approving it. This is cool technology that's COULD be used by PRAN to test their MPACs but ALL PHARMA could benefit in the same way. Nothing specific to PRAN and nothing near term as the FDA hasn't spoken up to how they will treat the new findings.
No, this is interesting from a macro AD perspective but of little direct application to PRAN.
Tanzi's new work is very interesting but it doesn't relate directly to PRAN. Why does everyone think PRAN will benefit? Maybe faster testing of compounds but all Pharma will benefit.
I'm sorry but this is a non event for me. I'm happy for Tanzi's success and hope it speeds the development of dsperately needed treatments. I just don't expect anything for my investment in PRAN.